Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$48.66 USD
-0.63 (-1.28%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $48.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Cytokinetics, Incorporated has a market cap of $5.90B, which represents its share price of $49.29 multiplied by its outstanding shares number of 119.66M. As a mid-cap company, CYTK's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CYTK 48.66 -0.63(-1.28%)
Will CYTK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CYTK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYTK
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
Company News for Sep 3, 2025
CYTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
Techne (TECH) Beats Q4 Earnings and Revenue Estimates
Other News for CYTK
1,2,3 Pullback Bullish appears for CYTK after 1.28% move
CYTK forms 1,2,3 Pullback Bullish on September 18
Cytokinetics Faces Lawsuit Over Misleading Investors
CYTK forms MACD Bearish Signal Line Cross on September 18
Cytokinetics (CYTK) Rises on Convertible Note Offering Plan